Stock Market announcement 

Bergen, Norway – October 20, 2020: The Norwegian listed company Lifecare AS
(LIFE-ME) has a 25% ownership in the German company Digital Diagnostics AG,
which has developed an accurate and reliable rapid test for Covid-19. 

Bionovate Technologies Corp. (BIIO), a swiss based company traded at Nasdaq OTC
Foreign, has announced a Share Exchange Agreement between Evergreen Solutions
Ltd. and Human Data AG to the United States Securities and Exchange Commission.

According to the announcement Human Data AG will, in exchange for 25% of the
shares in Digital Diagnostics AG, receive 54,270,000 shares in Bionovate
Technologies Corp. from Evergreen Solutions Ltd. 
Shares in Bionovate Technologies Corp. was traded at a price per share USD 4 on
October 19th, 2020, valuating the transaction of 25% of Digital Diagnostics AG
to USD 217,080,000.   

In the opinion of Lifecare, the transaction is subject for board approval in
Digital Diagnostics AG. Digital Diagnostics AG has not been notified of the
transaction, and the transaction is not registered in the German Trade Register.


Lifecare (LIFE-ME) is a Bergen-based technology company developing a miniature
sensor for correct and continuous monitoring of diabetics’ blood sugar. Its
patented technology is also used as a central component in a rapid test for
Covid-19 and as a measurement unit for reading out different biomarkers.

For more information, please contact:
Joacim Holter
CEO, Lifecare
joacim.holter@lifecare.no
+47 40 05 90 40